Q2 Earnings Estimate for CAPR Issued By Roth Capital

Capricor Therapeutics Inc (NASDAQ:CAPR - Free Report) - Roth Capital issued their Q2 2025 earnings per share (EPS) estimates for shares of Capricor Therapeutics in a research note issued on Tuesday, May 20th. Roth Capital analyst B. Pachaiyappan anticipates that the biotechnology company will earn ($0.47) per share for the quarter. Roth Capital has a "Buy" rating and a $31.00 price target on the stock. The consensus estimate for Capricor Therapeutics' current full-year earnings is ($1.21) per share. Roth Capital also issued estimates for Capricor Therapeutics' Q3 2025 earnings at $1.28 EPS, Q4 2025 earnings at $2.83 EPS, FY2025 earnings at $3.11 EPS, Q1 2026 earnings at ($0.27) EPS, Q2 2026 earnings at ($0.20) EPS, Q3 2026 earnings at ($0.15) EPS and Q4 2026 earnings at ($0.11) EPS.

Several other equities research analysts have also weighed in on the company. Wall Street Zen lowered Capricor Therapeutics from a "hold" rating to a "sell" rating in a report on Thursday, May 22nd. Cantor Fitzgerald reissued an "overweight" rating and issued a $30.00 price objective on shares of Capricor Therapeutics in a report on Wednesday, May 14th. Finally, HC Wainwright reissued a "buy" rating and issued a $77.00 price objective on shares of Capricor Therapeutics in a report on Monday, March 17th. One analyst has rated the stock with a sell rating and six have given a buy rating to the company's stock. According to data from MarketBeat, Capricor Therapeutics has an average rating of "Moderate Buy" and an average price target of $35.50.

Capricor Therapeutics Price Performance

Shares of NASDAQ CAPR traded down $0.10 during mid-day trading on Thursday, reaching $10.15. 389,390 shares of the company's stock were exchanged, compared to its average volume of 1,729,648. The firm has a market capitalization of $463.44 million, a price-to-earnings ratio of -9.61 and a beta of 0.85. Capricor Therapeutics has a 52 week low of $3.52 and a 52 week high of $23.40. The firm has a 50-day moving average price of $10.46 and a two-hundred day moving average price of $13.33.

Capricor Therapeutics (NASDAQ:CAPR - Get Free Report) last released its earnings results on Tuesday, May 13th. The biotechnology company reported ($0.53) EPS for the quarter, missing analysts' consensus estimates of ($0.33) by ($0.20). The business had revenue of $2.73 million for the quarter, compared to the consensus estimate of $3.16 million. Capricor Therapeutics had a negative return on equity of 112.95% and a negative net margin of 146.86%. During the same quarter in the previous year, the firm earned ($0.31) earnings per share.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the stock. Charles Schwab Investment Management Inc. grew its holdings in Capricor Therapeutics by 51.5% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 111,336 shares of the biotechnology company's stock valued at $1,536,000 after buying an additional 37,868 shares in the last quarter. Magnus Financial Group LLC purchased a new position in shares of Capricor Therapeutics during the fourth quarter worth about $276,000. Swiss National Bank purchased a new position in shares of Capricor Therapeutics during the fourth quarter worth about $930,000. JPMorgan Chase & Co. grew its holdings in shares of Capricor Therapeutics by 419.5% during the third quarter. JPMorgan Chase & Co. now owns 56,199 shares of the biotechnology company's stock worth $855,000 after purchasing an additional 45,381 shares in the last quarter. Finally, Alliancebernstein L.P. purchased a new stake in Capricor Therapeutics in the fourth quarter valued at approximately $183,000. Hedge funds and other institutional investors own 21.68% of the company's stock.

About Capricor Therapeutics

Capricor Therapeutics, Inc NASDAQ: CAPR is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor's lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.